Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | USP5 | P45974 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25265377 | 1.00 | FFAR1 (0.37) | FFAR1NOTUMKMOUSP5SMN1; SMN2 | |
| SCHEMBL15391066 | 0.81 | MAPT (0.37) | SMN1; SMN2LMNACYP2C9CYP2C19TSHR | |
| SCHEMBL16626878 | 0.79 | FFAR1 (0.38) | FFAR1LMNATSHRKMT2AALDH1A1 | |
| SCHEMBL25209479 | 0.79 | FFAR1 (0.38) | FFAR1LMNATSHRKMT2AALDH1A1 | |
| SCHEMBL28796325 | 0.79 | FFAR1 (0.38) | FFAR1NOTUMGABBR2GABBR1LMNA | |
| SCHEMBL16719274 | 0.79 | FFAR1 (0.38) | FFAR1NOTUMGABBR2GABBR1LMNA | |
| SCHEMBL28957053 | 0.78 | FFAR1 (0.37) | FFAR1TSHRALDH1A1MAPTL3MBTL1 | |
| SCHEMBL28957054 | 0.78 | FFAR1 (0.37) | FFAR1TSHRALDH1A1MAPTL3MBTL1 | |
| SCHEMBL16624822 | 0.75 | HTT (0.36) | — | |
| SCHEMBL24227162 | 0.74 | SELE (0.35) | SMN1; SMN2LMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115485276-B | Deuterated AKT kinase inhibitors | 南京正大天晴制药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117964620-A | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-113272304-B | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115843298-B | Salts and crystal forms of dihydropyrido [2,3-d ] pyrimidinone derivative | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-112480116-B | PKB inhibitors | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117677614-A | Heterocyclic compound with AKT kinase inhibition activity, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-115836069-B | Salts of dihydropyrido [2,3-d ] pyrimidinone derivatives, preparation method and application thereof | 南京正大天晴制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230321108-A1 | UNIT DOSAGE COMPOSITION OF AKT INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230286979-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230271958-A1 | SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| CN-115836069-A | Salt of dihydropyrido [2,3-d ] pyrimidone derivative, preparation method and application thereof | 南京正大天晴制药有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-110590606-B | Process for preparing pyrimidylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-105899492-B | Process for preparing pyrimidylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-113272304-A | AKT inhibitors | 南京正大天晴制药有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-112898210-A | Process for preparing pyrimidylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-112480116-A | PKB inhibitors | 南京正大天晴制药有限公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-110590606-A | Process for preparing pyrimidylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2019-12-20 | — | — | CN | disclosed |
| EP-2861583-B1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-9309204-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | PIK3CA, DHPS, PIK3CD | FFAR1 3067/4885NOTUM 2963/4885KMO 921/4885 |
| US-20230321108-A1 | UNIT DOSAGE COMPOSITION OF AKT INHIBITOR | AKT2, AKT1, PIK3R2 | FFAR1 789/4885NOTUM 442/4885KMO 4393/4885 |
| US-20230286979-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | FH, GRHPR, SDHB | FFAR1 1746/4885NOTUM 212/4885KMO 1722/4885 |
| US-20230271958-A1 | SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE | DCK, DPYD, UCK2 | FFAR1 1430/4885NOTUM 4135/4885KMO 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.